デフォルト表紙
市場調査レポート
商品コード
1193141

ブラストミセス症市場:製剤別、薬剤タイプ別、流通チャネル別:世界の機会分析・産業予測、2021-2031年

Blastomycosis Market By Formulation, By Drug Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: | 発行: Allied Market Research | ページ情報: 英文 240 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
ブラストミセス症市場:製剤別、薬剤タイプ別、流通チャネル別:世界の機会分析・産業予測、2021-2031年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 240 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ブラストミセス症は、木材や土壌に生息するブラストミセス・デルマティディスという真菌によって引き起こされる真菌感染症の一種です。

ブラストマイセスの胞子を吸い込むと、空気を通して体内に入るため、主に肺を侵し、肺炎を引き起こします。真菌は血液を介して体内の他の部位に広がります。ブラストミセス症の症状は、他の肺感染症の症状と似ていることが多く、咳、寝汗、筋肉痛や関節痛、体重減少、胸痛、疲労感などがあります。

ブラストミセス症感染が皮膚に広がった場合、軽度から中等度の症例では、アゾール、アリルアミン、エキノキャンディン、ポリエンなどの治療薬を投与することが可能です。

ブラストミセス症市場の成長を牽引する主な要因としては、ブラストミセス症治療のための新薬開発の増加、肺炎、結核、非感染性肺疾患などの慢性疾患の有病率上昇によるブラストミセス症患者の増加、ブラストミセス症の治療におけるアゾール系の高い普及率などが挙げられます。さらに、感染症の発生率や有病率の増加、免疫不全者(感染症にかかりやすい人)の増加が、市場の成長を促進しています。

例えば、米国疾病対策予防センターによると、2021年に米国で報告された結核(TB)患者は7,860人(10万人あたり2.4人の割合)です。米国では、最大で1,300万人が潜在性結核感染症を抱えて生活しています。このため、ブラストマイシスの患者数が増加し、ブラストマイシスの治療に対する需要が高まっています。したがって、このような要因が、ブラストミセス症治療薬の成長を促進します。

例えば、世界保健機関(WHO)によると、2021年に世界で3480万人がHIVと共存し、65万人がHIV関連の病気で死亡しています。これによると2021年にHIVを取得する人は150万人。したがって、これらのHIV患者は、HIVに対する免疫力が弱いため、ブラストミセス症にかかりやすくなっています。

しかし、不利な償還だけでなく、薬やブラストミセス症の薬剤の高コストなどで、市場の成長を妨げると予想されます。一方、新興諸国におけるアンメット・メディカル・デマンドや新興国における有利なビジネスチャンスは、今後、世界中のブラストミセス症治療薬メーカーに絶大なビジネスチャンスをもたらすと期待されています。

さらに、ヘルスケア事業は、免疫不全患者の増加、後天性免疫不全症候群(AIDS)の流行により、ブラストミセス症にかかりやすく、ブラストミセス症市場の成長を後押しするため、成長を示すと予測されます。また、ブラストミセス症に対する安全かつ効果的な治療薬の発見・開発の増加や、ブラストミセス症の治療におけるアゾール系薬剤の使用に関する意識の高まりが、ブラストミセス症市場の成長を後押ししています。このため、予測期間中に主要企業が市場に投資するための有益な機会を提供すると予想されます。

さらに、研究開発投資の増加、アゾールを用いた臨床研究の増加、先進国における資本所得の大幅な上昇、主要企業が採用する買収、提携、製品発売などの主な戦略の急増は、市場におけるブラストマイシスの需要を強化します。

例えば、2021年6月、Celon Laboratories Pvt. Ltd.は、真菌感染症の治療に用いられるアンフォテリシンB乳剤「AMFIGHT」の発売を発表しています。このエマルジョンベースの製剤は、リポソーム・アムホテリシンBに代わる、黒色真菌症対策に最適な製剤です。セロンは2013年からリポソーム・アムホテリシンBを製造していますが、ドイツから調達した重要な成分であるリポイドが入手できないため、市場の需要に応えられないでいました。この調達障害によるボトルネックを回避し、この薬の生産量を増やすために、セロンは代替となるエマルジョンベースの製剤を開発しました。AMFIGHTの発売は、同社の抗真菌剤製品群の強化につながります。この種の製品の上市は、ブラストミセス市場の成長を後押しします。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 ブラストミセス症市場:製剤別

  • 概要
    • 市場規模および予測
  • 錠剤
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 軟膏
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 粉体
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 液体
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第5章 ブラストミセス症市場:薬剤タイプ別

  • 概要
    • 市場規模および予測
  • アゾール系
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • ポリエン類
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第6章 ブラストミセス症市場:流通チャネル別

  • 概要
    • 市場規模・予測
  • 病院・調剤薬局
    • 主な市場動向、成長要因と機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • オンライン薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別
  • 小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場シェア分析:国別

第7章 ブラストミセス症市場:地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米市場規模・予測:剤形別
    • 北米市場規模・予測:薬剤タイプ別
    • 北米市場規模・予測:流通チャネル別
    • 北米市場規模・予測:国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な動向と機会
    • 欧州の市場規模・予測:製剤別
    • 欧州市場規模・予測:薬剤タイプ別
    • 欧州市場規模・予測:流通チャネル別
    • 欧州市場規模・予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他の欧州地域
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測:製剤別
    • アジア太平洋地域の市場規模・予測:薬剤タイプ別
    • アジア太平洋地域の市場規模・予測:流通チャネル別
    • アジア太平洋地域の市場規模・予測:国別
      • 中国
      • インド
      • オーストラリア
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測:製剤別
    • LAMEAの市場規模・予測:薬剤タイプ別
    • LAMEAの市場規模・予測:流通チャネル別
    • LAMEAの市場規模・予測:国別
      • ブラジル
      • 南アフリカ共和国
      • サウジアラビア
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • Pfizer Inc.
  • Sanofi
  • Merck and Company
  • GSK
  • johnson and johnson md&d
  • Abbott Laboratories
  • CELON LABORATORIES LIMITED
  • Sun Pharmaceuticals Ltd
  • Astellas Pharma Inc.
  • Cipla Ltd
図表

LIST OF TABLES

  • TABLE 1. GLOBAL BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. BLASTOMYCOSIS MARKET FOR TABLETS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. BLASTOMYCOSIS MARKET FOR TABLETS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. BLASTOMYCOSIS MARKET FOR OINTMENT, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. BLASTOMYCOSIS MARKET FOR OINTMENT, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. BLASTOMYCOSIS MARKET FOR POWDER, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. BLASTOMYCOSIS MARKET FOR POWDER, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. BLASTOMYCOSIS MARKET FOR LIQUID, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. BLASTOMYCOSIS MARKET FOR LIQUID, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. GLOBAL BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. BLASTOMYCOSIS MARKET FOR AZOLES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. BLASTOMYCOSIS MARKET FOR AZOLES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. BLASTOMYCOSIS MARKET FOR POLYENES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. BLASTOMYCOSIS MARKET FOR POLYENES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. BLASTOMYCOSIS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. BLASTOMYCOSIS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. GLOBAL BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. BLASTOMYCOSIS MARKET FOR HOSPITAL AND CLINICAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. BLASTOMYCOSIS MARKET FOR HOSPITAL AND CLINICAL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. BLASTOMYCOSIS MARKET FOR ONLINE PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. BLASTOMYCOSIS MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. BLASTOMYCOSIS MARKET FOR RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. BLASTOMYCOSIS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. BLASTOMYCOSIS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. NORTH AMERICA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. NORTH AMERICA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. NORTH AMERICA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. NORTH AMERICA BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. U.S. BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. U.S. BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. U.S. BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. CANADA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. CANADA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. CANADA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. MEXICO BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. MEXICO BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. MEXICO BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. EUROPE BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. EUROPE BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. EUROPE BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. EUROPE BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. GERMANY BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. GERMANY BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. GERMANY BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. FRANCE BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. FRANCE BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. FRANCE BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. UK BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. UK BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. UK BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ITALY BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ITALY BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. ITALY BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. SPAIN BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. SPAIN BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. SPAIN BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. REST OF EUROPE BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. REST OF EUROPE BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. REST OF EUROPE BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. CHINA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. CHINA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. CHINA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. INDIA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. INDIA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. INDIA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. AUSTRALIA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. AUSTRALIA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. AUSTRALIA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. SOUTH KOREA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. SOUTH KOREA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. SOUTH KOREA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. LAMEA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. LAMEA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. LAMEA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. LAMEA BLASTOMYCOSIS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. BRAZIL BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. BRAZIL BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. BRAZIL BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. SOUTH AFRICA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. SOUTH AFRICA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. SOUTH AFRICA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. SAUDI ARABIA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. SAUDI ARABIA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. SAUDI ARABIA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. REST OF LAMEA BLASTOMYCOSIS MARKET, BY FORMULATION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. REST OF LAMEA BLASTOMYCOSIS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. REST OF LAMEA BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 96.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 97.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 98.PFIZER INC.: NET SALES
  • TABLE 99.PFIZER INC.: KEY STRATERGIES
  • TABLE 100.SANOFI: COMPANY SNAPSHOT
  • TABLE 101.SANOFI: OPERATING SEGMENTS
  • TABLE 102.SANOFI: PRODUCT PORTFOLIO
  • TABLE 103.SANOFI: NET SALES
  • TABLE 104.SANOFI: KEY STRATERGIES
  • TABLE 105.MERCK AND COMPANY: COMPANY SNAPSHOT
  • TABLE 106.MERCK AND COMPANY: OPERATING SEGMENTS
  • TABLE 107.MERCK AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 108.MERCK AND COMPANY: NET SALES
  • TABLE 109.MERCK AND COMPANY: KEY STRATERGIES
  • TABLE 110.GSK: COMPANY SNAPSHOT
  • TABLE 111.GSK: OPERATING SEGMENTS
  • TABLE 112.GSK: PRODUCT PORTFOLIO
  • TABLE 113.GSK: NET SALES
  • TABLE 114.GSK: KEY STRATERGIES
  • TABLE 115.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT
  • TABLE 116.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS
  • TABLE 117.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO
  • TABLE 118.JOHNSON AND JOHNSON MD&D: NET SALES
  • TABLE 119.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES
  • TABLE 120.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 121.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 122.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 123.ABBOTT LABORATORIES: NET SALES
  • TABLE 124.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 125.CELON LABORATORIES LIMITED: COMPANY SNAPSHOT
  • TABLE 126.CELON LABORATORIES LIMITED: OPERATING SEGMENTS
  • TABLE 127.CELON LABORATORIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 128.CELON LABORATORIES LIMITED: NET SALES
  • TABLE 129.CELON LABORATORIES LIMITED: KEY STRATERGIES
  • TABLE 130.SUN PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 131.SUN PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 132.SUN PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 133.SUN PHARMACEUTICALS LTD: NET SALES
  • TABLE 134.SUN PHARMACEUTICALS LTD: KEY STRATERGIES
  • TABLE 135.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 136.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
  • TABLE 137.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 138.ASTELLAS PHARMA INC.: NET SALES
  • TABLE 139.ASTELLAS PHARMA INC.: KEY STRATERGIES
  • TABLE 140.CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 141.CIPLA LTD: OPERATING SEGMENTS
  • TABLE 142.CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 143.CIPLA LTD: NET SALES
  • TABLE 144.CIPLA LTD: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.BLASTOMYCOSIS MARKET SEGMENTATION
  • FIGURE 2.BLASTOMYCOSIS MARKET,2021-2031
  • FIGURE 3.BLASTOMYCOSIS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.BLASTOMYCOSIS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.BLASTOMYCOSIS MARKET,BY FORMULATION,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF TABLETS BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF OINTMENT BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF POWDER BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF LIQUID BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 17.BLASTOMYCOSIS MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF AZOLES BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF POLYENES BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHERS BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 21.BLASTOMYCOSIS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITAL AND CLINICAL PHARMACY BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY BLASTOMYCOSIS MARKET,2021-2031(%)
  • FIGURE 25.BLASTOMYCOSIS MARKET BY REGION,2021
  • FIGURE 26.U.S. BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 27.CANADA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 28.MEXICO BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 29.GERMANY BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 30.FRANCE BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 31.UK BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 32.ITALY BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 33.SPAIN BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF EUROPE BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 36.INDIA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 37.AUSTRALIA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH KOREA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 39.REST OF ASIA-PACIFIC BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 40.BRAZIL BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 41.SOUTH AFRICA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 42.SAUDI ARABIA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF LAMEA BLASTOMYCOSIS MARKET,2021-2031($MILLION)
  • FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 48.COMPETITIVE DASHBOARD
  • FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 50.PFIZER INC..: NET SALES ($MILLION)
  • FIGURE 51.SANOFI.: NET SALES ($MILLION)
  • FIGURE 52.MERCK AND COMPANY.: NET SALES ($MILLION)
  • FIGURE 53.GSK.: NET SALES ($MILLION)
  • FIGURE 54.JOHNSON AND JOHNSON MD&D.: NET SALES ($MILLION)
  • FIGURE 55.ABBOTT LABORATORIES.: NET SALES ($MILLION)
  • FIGURE 56.CELON LABORATORIES LIMITED.: NET SALES ($MILLION)
  • FIGURE 57.SUN PHARMACEUTICALS LTD.: NET SALES ($MILLION)
  • FIGURE 58.ASTELLAS PHARMA INC..: NET SALES ($MILLION)
  • FIGURE 59.CIPLA LTD.: NET SALES ($MILLION)
目次
Product Code: A15629

Blastomycosis is a type of fungal infection caused by the fungus Blastomyces dermatitidis, which grows in wood and soil. Spores of Blastomyces enter the body through air, when inhaled, thus it mainly affects the lung and causes pneumonia. Fungi are spread through the bloodstream to other parts of the body. The symptoms of blastomycosis are often similar to the symptoms of other lung infections and can include cough, night sweats, muscle aches or joint pain, weight loss, chest pain, and fatigue.

When blastomycosis infection is spread in the skin, treatments such as azole, allylamines, echinocandins, and polyenes can be given in mild to moderate cases of blastomycosis infection.

Major factors driving the growth of the blastomycosis market include a rise in the development of new medicine for the treatment of blastomycosis infection, an increase in the prevalence rate of chronic diseases such as pneumonia, tuberculosis, a non-infectious pulmonary disease that have led to increases in a number of blastomycosis patients, and high adoption of azoles for the treatment of blastomycosis. Further, growth in the incidence and prevalence rate of infectious diseases and the rise in the population of immunocompromised (prone to infectious diseases) individuals enhance the growth of this market.

For instance, according to the Centers for Disease Control and Prevention, 7,860 tuberculosis (TB) cases were reported in the U.S. in 2021 (a rate of 2.4 per 100,000 persons). In the U.S., up to 13 million people live with latent TB infection. This has led to an increase in the number of blastomycosis patients, which increases the demand for blastomycosis treatment. Hence, such factors drive the growth of blastomycosis treatment.

For instance, according to World Health Organization (WHO), 34.8 million people were living with HIV worldwide in 2021 and 650,000 people died of HIV-related illnesses worldwide in 2021. According to this 1.5 million people acquiring HIV in 2021. Hence, these HIV patients are more vulnerable to blastomycosis, owing to weak immunity to HIV.

However, unfavorable reimbursements as well as complications such as high costs of medicine and drugs for blastomycosis are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for blastomycosis medicine manufacturers worldwide in the future.

Furthermore, the healthcare business is projected to witness growth owing to a rise in immunocompromised patients, a rise in the prevalence of acquired immunodeficiency syndrome (AIDS), that are more vulnerable to blastomycosis, and a boost in the growth of the blastomycosis market. In addition, an increase in the discovery & development of safe and effective medicine for blastomycosis and a rise in awareness regarding the use of azoles for the treatment of blastomycosis drive the growth of the blastomycosis market. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

Moreover, a rise in R&D investments, an increase in azoles-assisted clinical research studies, a significant rise in the capital income in developed countries, and a surge in key strategies such as acquisition, collaboration, and product launch, adopted by key players strengthen the demand for blastomycosis in the market.

For instance, in June 2021, Celon Laboratories Pvt. Ltd. announced the launch of AMFIGHT, an amphotericin B emulsion, used in the treatment of fungal infection. The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany - lipoids. To bypass the bottleneck caused by this sourcing obstacle and increase the production of this medication, Celon developed an alternative, an emulsion-based formulation. The launch of AMFIGHT will help the company to strengthen its anti-fungal product portfolio. This type of product launch boosts the growth of the blastomycosis market.

The blastomycosis market is segmented on the basis of formulation, drug type, distribution channel, and region. On the basis of formulation, the market is classified into tablets, ointment, powder, and liquid. On the basis of drug type, the market is classified into azoles, polyenes, and others. Depending on the distribution channel, it is fragmented into hospital & clinical pharmacy, online pharmacy, and retail pharmacy. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Abbott Laboratories, Astellas Pharma Inc., Celon Laboratories Pvt. Ltd., Cipla Ltd, GlaxoSmithKline plc, Johnson and Johnson, Merck KGaA, Pfizer Inc., Sanofi S.A., and Sun Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blastomycosis market analysis from 2021 to 2031 to identify the prevailing blastomycosis market opportunities.

Market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.

An in-depth analysis of the blastomycosis market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes an analysis of the regional as well as global blastomycosis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Azoles
  • Polyenes
  • Others

By Distribution Channel

  • Hospital and Clinical Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

By Formulation

  • Tablets
  • Ointment
  • Powder
  • Liquid

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA
  • Key Market Players
    • Pfizer Inc.
    • Sanofi
    • Merck and Company
    • GSK
    • johnson and johnson md&d
    • Abbott Laboratories
    • CELON LABORATORIES LIMITED
    • Sun Pharmaceuticals Ltd
    • Astellas Pharma Inc.
    • Cipla Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: BLASTOMYCOSIS MARKET, BY FORMULATION

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Tablets
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Ointment
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Powder
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country
  • 4.5 Liquid
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market share analysis by country

CHAPTER 5: BLASTOMYCOSIS MARKET, BY DRUG TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Azoles
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Polyenes
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country
  • 5.4 Others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market share analysis by country

CHAPTER 6: BLASTOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital and Clinical Pharmacy
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Online Pharmacy
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Retail Pharmacy
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: BLASTOMYCOSIS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Formulation
    • 7.2.3 North America Market size and forecast, by Drug Type
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Formulation
      • 7.2.5.1.3 Market size and forecast, by Drug Type
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Formulation
      • 7.2.5.2.3 Market size and forecast, by Drug Type
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Formulation
      • 7.2.5.3.3 Market size and forecast, by Drug Type
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Formulation
    • 7.3.3 Europe Market size and forecast, by Drug Type
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Formulation
      • 7.3.5.1.3 Market size and forecast, by Drug Type
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Formulation
      • 7.3.5.2.3 Market size and forecast, by Drug Type
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Formulation
      • 7.3.5.3.3 Market size and forecast, by Drug Type
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Formulation
      • 7.3.5.4.3 Market size and forecast, by Drug Type
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Formulation
      • 7.3.5.5.3 Market size and forecast, by Drug Type
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Formulation
      • 7.3.5.6.3 Market size and forecast, by Drug Type
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Formulation
    • 7.4.3 Asia-Pacific Market size and forecast, by Drug Type
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 China
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Formulation
      • 7.4.5.1.3 Market size and forecast, by Drug Type
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 India
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Formulation
      • 7.4.5.2.3 Market size and forecast, by Drug Type
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Formulation
      • 7.4.5.3.3 Market size and forecast, by Drug Type
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 South Korea
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Formulation
      • 7.4.5.4.3 Market size and forecast, by Drug Type
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 Rest of Asia-Pacific
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Formulation
      • 7.4.5.5.3 Market size and forecast, by Drug Type
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Formulation
    • 7.5.3 LAMEA Market size and forecast, by Drug Type
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Formulation
      • 7.5.5.1.3 Market size and forecast, by Drug Type
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 South Africa
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Formulation
      • 7.5.5.2.3 Market size and forecast, by Drug Type
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 Saudi Arabia
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Formulation
      • 7.5.5.3.3 Market size and forecast, by Drug Type
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Formulation
      • 7.5.5.4.3 Market size and forecast, by Drug Type
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Pfizer Inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Sanofi
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Merck and Company
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 GSK
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 johnson and johnson md&d
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Abbott Laboratories
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 CELON LABORATORIES LIMITED
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Sun Pharmaceuticals Ltd
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Astellas Pharma Inc.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Cipla Ltd
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments